Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir

Xenobiotica

Volumn 36, Issue 12, 2006, Pages 1165-1177

  Nekvindova J ^a   Masek V ^a   Veinlichova A ^a   Anzenbacherova E ^a   Anzenbacher, P ^a   Zidek Z ^b   Holy A ^c  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Adefovir; Antivirals; Cytochromes P450 (CYP); Tenofovir

Indexed keywords

4 HYDROXYDICLOFENAC; 6 HYDROXYBUFURALOL; 6 HYDROXYCHLORZOXAZONE; 6BETA HYDROXYTESTOSTERONE; ADEFOVIR; ADEFOVIR DIPIVOXIL; BUFURALOL; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DICLOFENAC; PRODRUG; TENOFOVIR; TENOFOVIR DISOPROXIL; TESTOSTERONE DERIVATIVE;

ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; LUMINESCENCE;

ADENINE; ANTIVIRAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; PHOSPHONIC ACIDS; PRODRUGS;

EID: 33845644907     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600839344     Document Type: Article

References (24)

1. Anzenbacher P, Anzenbacherová E. 2001. Cytochromes P450 and metabolism of xenobiotics. Cell Molecular Life Science 58:737-747.
2. Bachmann KA, Lewis JD, Fuller MA, Bonfiglio MF, editors. 2004 Drug interactions handbook. 2nd ed. Hudson, OH: Lexi-Comp.
3. Boobis AR. 1999. EUROCYP: in vitro approaches to predict drug metabolism and interactions in man in drug development. ISSX Proceedings 14: 8.
4. Bourrie M, Meunier V, Berger Y, Fabre G. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapy 277:321-332.
5. Boxenbaum H. 1999. Human in vivo competitive inhibition of P450 substrates: increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition. Journal of Pharmacology and Pharmaceutical Science 2:89-91.
6. Burlingham BT, Widlanski TS. 2003. An intuitive look at the relationship of Ki and IC50: A more general use for the Dixon plot. Journal of Chemistry Education 80:214-218.
7. Chang TKH, Waxman DJ. 1998. Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as a substrate. In: Phillips IR, Shephard EA, editors. Cytochrome P450 protocols. Totowa, NJ: Humana. pp 103-122.
8. Cornish-Bowden A. 1995. Fundamentals of enzyme kinetics. 2nd ed. London: Portland.
9. Crespi CL, Chang TKH, Waxman DJ. 1998. CYP2D6-dependent bufuralol 1′-hydroxylation assayed by reversed-phase ion-pair high-performance liquid chromatography with fluorescence detection. In: Phillips IR, Shephard EA, editors. Cytochrome P450 protocols. Totowa, NJ: Humana. pp 141-146.
10. DeClercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecoque C, Snoeck R, Ying C, Hockova D, Holy A. 2005. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy) alkoxy]-2,4-diaminopyrimidines. Nucleosides and Nucleotide Nucleic Acids 24:331-341.
11. Donato MT, Jimenéz N, Castell JV, Gómez-Lechón MJ. 2004. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metabolism and Disposition 32:699-706.
12. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. 1986. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation. Journal of Biology and Chemistry 261:5051-5060.
13. Guengerich FP. 2005. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450, structure, mechanism and biochemistry. New York, NY: Kluwer/Plenum. pp 377-530.
14. Holý A. 2003. Phosphonomethoxyalkyl analogs of nucleotides. Current Pharmaceutical Design 9:2567-2592.
15. Kearney BP, Flaherty JF, Shah J. 2004. Tenofovir disoproxil fumarate, clinical pharmacology and pharmacokinetics. Clinical Pharmacokinetics 43:595-612.
16. Lucas D, Menez JF, Berthou F. 1996. Chlorzoxazone: an in vitro and in vivo substrate probe for liver CYP2E1. Methods in Enzymology 272:115-123.
17. Phillips IR, Shephard EA, editors. 1998. Cytochrome P450 protocols. Totowa, NJ: Humana.
18. Segel IH. 1975. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York, NY: Wiley.
19. Shaw JP, Louie MS, Krishnamurthy VV, Arimilli MN, Jones RJ, Bidgood AM, Lee WA, Cundy KC. 1997. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metabolism and Disposition 25:362-366.
20. Stiborová M, Borek-Dohalská L, Hodek P, Mráz J, Frei E. 2002. New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Archives in Biochemistry and Biophysics 403:41-49.
21. Tassaneeyakul W, Veronese ME, Birkett DJ, Miners JO. 1993. High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, putative cytochrome P450 2E1 activity, in human liver microsomes. Journal of Chromatography 616:73-78.
22. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. 2001. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. Journal of Clinical Pharmacology 41:1149-1179.
23. Waxman DJ, Chang TKH. 1998. Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation. In: Phillips IR, Shephard EA, editors. Cytochrome P450 protocols. Totowa, NJ: Humana. pp 111-116.
24. Yamazaki H, Shimada T. 1998. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6β-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metabolism and Disposition 26:1053-1057.